Moreover, the most recently updated AHS position statement now recommends CGRP-targeted therapies, including gepants, as first-line treatment options for the preventive treatment of migraine, stating that the cumulative evidence for their efficacy, safety, and tolerability is significantly greater than that for any established migraine preventive therapy [25]. The gene discussed is CALCA; the disease is migraine disorder.